Файловый архив студентов. Файловый архив студентов.
1330 вузов, 5508 предметов.
/ Регистрация
FAQ Обратная связь Вопросы и предложения
Добавил:
kiopkiopkiop18@yandex.ru t.me/Prokururor I Вовсе не секретарь, но почту проверяю Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Ростовский Государственный Медицинский Университет
Предмет:
Медицина общая
Файл:

Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_5667_Библиотеки_им_академика_М_И_Перельмана

.pdf
Скачиваний:
0
Добавлен:
15.09.2026
Размер:
10 Мб
Скачать
☆
3 Carbohydrate-Based Antiviral Vaccines
Данная книга находится в списке для перевода на русский язык сайта https://meduniver.com/
96
this system appear to be critical for the stimulation and activation of antigenspecific cellular and humoral immune responses. The proprietary, saponinbased Matrix M™ adjuvant has shown potent and welltolerated immunostimulatory effects by inducing the influx of APCs into the site of injection and enhancing antigen presen­tation in the lymph nodes[200, 201]. Notably, MatrixM has been licensed as part of Novavax recombinant nanoparticle subunit vaccine (NVAXCoV2373) derived from the Sprotein, acting by boosting Bcell and Tcell immunity for elicitation of more potent immune responses while also enabling dosesparing[202]. NVXCoV2373has been successfully evaluated in clinical trials, demonstrating high vaccine efficacy against several SARSCoV2 variants with an acceptable safety profile [203, 204], which has led to its recent approval by the European Medicines Agency. This saponin adjuvanted proteinbased vaccine highlights the promise of saponin adjuvants and subunit vaccines to prevent not only traditional but also emerging viral diseases, including COVID19 and potential new pandemics associated with further coronavi­rus infections.
3.7 Conclusions and Outlook
Viral glycosylation is a process mediated by the hostcell machinery that decorates the surface proteins of several pathogens with cell glycans, including the envelope glycoprotein (Env) of HIV1, hemagglutinin glycoprotein (HA) of influenza virus, the envelope glycoproteins (E1 and E2) of HCV, the glycoprotein (GP) of EBOV, the coronavirus glycoprotein spike (S), and others. This protein glycosylation is characterized by high structural variation and is essential for the viral lifecycle and pathogenesis, playing a key role in specific viral functions such as hostcell attachment and entry, infectivity, and replication. Moreover, these viral carbohy­drates form a glycan shield that has important implications for host immune responses to infection, protecting internal protein epitopes from immune recogni­tion while also exposing potential targets for vaccine and drug development. For instance, the conserved oligomannosetype Nglycans of some envelope glycopro­teins involved in transinfection and immune evasion also serve as neutralizing antibody epitopes or binding receptors for CBAs to fight against viral infection.
Despite significant recent research on the development of carbohydrate vaccines and therapies against viral diseases, much further work is needed for the translation of additional glycanbased candidates into clinical applications in humans. Increased knowledge of viral glycobiology and sitespecific protein glycosylation, as well as a better understanding of the immunological basis that drives viral diversity, will aid in guiding the rational design of nextgeneration vaccines and antiviral ther­apeutics in the future.
Acknowledgments
Funding from the European Research Council (ERC2016STG716878 “ADJUV ANT VACCINES”) and the Spanish Ministry of Science and Innovation/State
References
Research Agency (MCIN/AEI) (CTQ201787530R, RYC201517888 to A.F.T.; PRE2018085772 to A.P.) is gratefully acknowledged. We thank Dr. Iñaki Bastida for assistance with the preparation of the manuscript. A F.T. thanks Raquel Fernández for inspiration.
References
1 Liang, F., Guan, P., Wu, W. etal. (2018). A review of documents prepared by
international organizations about influenza pandemics, including the 2009 pandemic: a bibliometric analysis. BMC Infectious Diseases 18: 383.
2 Eisinger, R.W. and Fauci, A.S. (2018). Ending the HIV/AIDS pandemic. Emerging
Infectious Diseases 24 (3): 413–416.
3 Lai, C.C., Shih, T.P., Ko, W.C. etal. (2020). Severe acute respiratory syndrome
coronavirus 2 (SARSCoV2) and coronavirus disease2019 (COVID19): the epidemic and the challenges. International Journal of Antimicrobial Agents 55 (3): 105924.
4 Ringelhan, M., McKeating, J.A., and Protzer, U. (2017). Viral hepatitis and liver
cancer. Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences 372 (1732): 20160274.
5 Crosbie, E.J., Einstein, M.H., Franceschi, S., and Kitchener, H.C. (2013). Human
papillomavirus and cervical cancer. Lancet 382 (9895): 889–899.
6 Pollard, A.J. and Bijker, E.M. (2021). A guide to vaccinology: from basic principles
to new developments. Nature Reviews. Immunology 21: 83–100.
7 Watanabe, Y., Bowden, T.A., Wilson, I.A., and Crispin, M. (2019). Exploitation of
glycosylation in enveloped virus pathobiology. Biochimica et Biophysica Acta, General Subjects 1863 (10): 1480–1497.
8 Helenius, A. and Aebi, M. (2004). Roles of Nlinked glycans in the endoplasmic
reticulum. Annual Review of Biochemistry 73 (1): 1019–1049.
9 Vigerust, D.J. and Shepherd, V.L. (2007). Virus glycosylation: role in virulence and
immune interactions. Trends in Microbiology 15: 211–218.
10 RerksNgarm, S., Pitisuttithum, P., Nitayaphan, S. etal. (2009). Vaccination with
ALVAC and AIDSVAX to prevent HIV1infection in Thailand. The New England Journal of Medicine 361 (23): 2209–2220.
11 Corey, L., Gilbert, P.B., Tomaras, G.D. etal. (2015). Immune correlates of vaccine
protection against HIV1 acquisition. Science Translational Medicine 7 (310): 310rv7.
12 Stephenson, K.E., Wagh, K., Korber, B., and Barouch, D.H. (2020). Vaccines and
broadly neutralizing antibodies for HIV1 prevention. Annual Review of Immunology 38: 673–703.
13 Behrens, A.J., Seabright, G.E., and Crispin, M. (2017). Targeting glycans of HIV
envelope glycoproteins for vaccine design. In: Chemical Biology of Glycoproteins (ed. Z. Tan and L.X. Wang), 300–357. Cambridge: Royal Society of Chemistry.
14 Sok, D. and Burton, D.R. (2018). Recent progress in broadly neutralizing
antibodies to HIV. Nature Immunology 19: 1179–1188.
97
3 Carbohydrate-Based Antiviral Vaccines
Данная книга находится в списке для перевода на русский язык сайта https://meduniver.com/
98
15 Haynes, B.F., Burton, D.R., and Mascola, J.R. (2019). Multiple roles for HIV
broadly neutralizing antibodies. Science Translational Medicine 11 (516): eaaz2686.
16 Haynes, B.F. and Verkoczy, L. (2014). Host controls of HIV neutralizing
antibodies. Science 344 (6184): 588–589.
17 Walsh, S.R. and Seaman, M.S. (2021). Broadly neutralizing antibodies for HIV1
prevention. Frontiers in Immunology 12: 712122.
18 Seabright, G.E., Doores, K.J., Burton, D.R., and Crispin, M. (2019). Protein and
glycan mimicry in HIV vaccine design. Journal of Molecular Biology 431 (12): 2223–2247.
19 Bastida, I. and FernándezTejada, A. (2020). Synthetic carbohydratebased HIV1
vaccines. Drug Discovery Today: Technologies 3536: 45–56.
20 FernándezTejada, A., Haynes, B.F., and Danishefsky, S.J. (2015). Designing
synthetic vaccines for HIV. Expert Review of Vaccines 14 (6): 815–831.
21 Trkola, A., Purtscher, M., Muster, T. etal. (1996). Human monoclonal antibody
2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. Journal of Virology 70 (2): 1100–1108.
22 Mascola, J.R., Stiegler, G., Vancott, T.C. etal. (2000). Protection of macaques
against vaginal transmission of a pathogenic HIV1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nature Medicine 6 (2): 207–210.
23 Hessell, A.J., Rakasz, E.G., Poignard, P. etal. (2009). Broadly neutralizing human
antiHIV antibody 2G12 Is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers. PLoS Pathogens 5 (5): e1000433.
24 Sanders, R.W., Venturi, M., Schiffner, L. etal. (2002). The mannosedependent
epitope for neutralizing antibody 2G12 on human immunodeficiency virus type 1 glycoprotein gp120. Journal of Virology 76 (14): 7293–7305.
25 Scanlan, C.N., Pantophlet, R., Wormald, M.R. etal. (2002). The broadly
neutralizing antihuman immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of α1→2mannose residues on the outer face of gp120. Journal of Virology 76 (14): 7306–7321.
26 Calarese, D.A., Scanlan, C.N., Zwick, M.B. etal. (2003). Antibody domain
exchange is an immunological solution to carbohydrate cluster recognition. Science 300 (5628): 2065–2071.
27 Wang, L.X., Ni, J., Singh, S., and Li, H. (2004). Binding of highmannosetype
oligosaccharides and synthetic oligomannose clusters to human antibody 2G12. Chemistry & Biology 11 (1): 127–134.
28 Lee, H.K., Scanlan, C.N., Huang, C.Y. etal. (2004). Reactivitybased onepot
synthesis of oligomannoses: defining antigens recognized by 2G12, a broadly neutralizing antiHIV1 antibody. Angewandte Chemie, International Edition 43 (8): 1000–1003.
29 Calarese, D.A., Lee, H.K., Huang, C.Y. etal. (2005). Dissection of the
carbohydrate specificity of the broadly neutralizing antiHIV1 antibody 2G12. Proceedings of the National Academy of Sciences of the United States of America 102 (38): 13372–13377.
References
30 Adams, E.W., Ratner, D.M., Bokesch, H.R. etal. (2004). Oligosaccharide and
glycoprotein microarrays as tools in HIV glycobiology. Chemistry & Biology 11 (6): 875–881.
31 Toonstra, C., Wu, L., Li, C. etal. (2018). Topdown chemoenzymatic approach to
synthesizing diverse highmannose Nglycans and related neoglycoproteins for carbohydrate microarray analysis. Bioconjugate Chemistry 29 (6): 1911–1921.
32 Li, H. and Wang, L.X. (2004). Design and synthesis of a templateassembled
oligomannose cluster as an epitope mimic for human HIVneutralizing antibody 2G12. Organic & Biomolecular Chemistry 2 (4): 483–488.
33 Ni, J., Song, H., Wang, Y. etal. (2006). Toward a carbohydratebased HIV1
vaccine: synthesis and immunological studies of oligomannosecontaining glycoconjugates. Bioconjugate Chemistry 17 (2): 493–500.
34 Mandal, M., Dudkin, V.Y., Geng, X., and Danishefsky, S.J. (2004). In pursuit of
carbohydratebased HIV vaccines, part 1: the total synthesis of hybridtype gp120 fragments. Angewandte Chemie, International Edition 43 (19): 2557–2561.
35 Geng, X., Dudkin, V.Y., Mandal, M., and Danishefsky, S.J. (2004). In pursuit of
carbohydratebased HIV vaccines, part 2: the total synthesis of highmannosetype gp120 fragments— evaluation of strategies directed to maximal convergence. Angewandte Chemie, International Edition 43 (19): 2562–2565.
36 Dudkin, V.Y., Orlova, M., Geng, X. etal. (2004). Toward fully synthetic
carbohydratebased HIV antigen design: on the critical role of bivalency. Journal of the American Chemical Society 126 (31): 9560–9562.
37 Wang, J., Li, H., Zou, G., and Wang, L.X. (2007). Novel templateassembled
oligosaccharide clusters as epitope mimics for HIVneutralizing antibody 2G12. Design, synthesis, and antibody binding study. Organic & Biomolecular Chemistry 5 (10): 1529–1540.
38 Krauss, I.J., Joyce, J.G., Finnefrock, A.C. etal. (2007). Fully synthetic carbohydrate
HIV antigens designed on the logic of the 2G12 antibody. Journal of the American Chemical Society 129 (36): 11042–11044.
39 Joyce, J.G., Krauss, I.J., Song, H.C. etal. (2008). An oligosaccharidebased HIV1
2G12mimotope vaccine induces carbohydratespecific antibodies that fail to neutralize HIV1 virions. Proceedings of the National Academy of Sciences 105 (41): 15684–15689.
40 Wang, S.K., Liang, P.H., Astronomo, R.D. etal. (2008). Targeting the
carbohydrates on HIV1: interaction of oligomannose dendrons with human monoclonal antibody 2G12 and DCSIGN. Proceedings of the National Academy of Sciences 105 (10): 3690–3695.
41 Kabanova, A., Adamo, R., Proietti, D. etal. (2010). Preparation, characterization
and immunogenicity of HIV1 related highmannose oligosaccharidesCRM197 glycoconjugates. Glycoconjugate Journal 27 (5): 501–513.
42 Astronomo, R.D., Lee, H.K., Scanlan, C.N. etal. (2008). A glycoconjugate antigen
based on the recognition motif of a broadly neutralizing human immunodeficiency virus antibody, 2G12, is immunogenic but elicits antibodies unable to bind to the self glycans of gp120. Journal of Virology 82 (13): 6359–6368.
99
3 Carbohydrate-Based Antiviral Vaccines
Данная книга находится в списке для перевода на русский язык сайта https://meduniver.com/
100
43 Trattnig, N., Mayrhofer, P., Kunert, R. etal. (2019). Comparative antigenicity of
thiourea and adipic amide linked neoglycoconjugates containing modified oligomannose epitopes for the carbohydratespecific antiHIV antibody 2G12. Bioconjugate Chemistry 30 (1): 70–82.
44 Astronomo, R.D., Kaltgrad, E., Udit, A.K. etal. (2010). Defining criteria for
oligomannose immunogens for HIV using icosahedral virus capsid scaffolds. Chemistry & Biology 17 (4): 357–370.
45 Doores, K.J., Fulton, Z., Hong, V. etal. (2010). A nonself sugar mimic of the HIV
glycan shield shows enhanced antigenicity. Proceedings of the National Academy of Sciences 107 (40): 17107–17112.
46 MacPherson, I.S., Temme, J.S., Habeshian, S. etal. (2011). Multivalent
glycocluster design through directed evolution. Angewandte Chemie, International Edition 50 (47): 11238–11242.
47 Temme, J.S., MacPherson, I.S., DeCourcey, J.F., and Krauss, I.J. (2014). High
temperature SELMA: evolution of DNAsupported oligomannose clusters which are tightly recognized by HIV bnAb 2G12. Journal of the American Chemical Society 136 (5): 1726–1729.
48 Horiya, S., Bailey, J.K., Temme, J.S. etal. (2014). Directed evolution of multivalent
glycopeptides tightly recognized by HIV antibody 2G12. Journal of the American Chemical Society 136 (14): 5407–5415.
49 Bailey, J.K., Nguyen, D.N., Horiya, S., and Krauss, I.J. (2016). Synthesis of
multivalent glycopeptide conjugates that mimic an HIV epitope. Tetrahedron 72 (40): 6091–6098.
50 Nguyen, D.N., Xu, B., Stanfield, R.L. etal. (2019). Oligomannose glycopeptide
conjugates elicit antibodies targeting the glycan core rather than its extremities. ACS Central Science 5 (2): 237–249.
51 Nguyen, D.N., Redman, R.L., Horiya, S. etal. (2020). The impact of sustained
immunization regimens on the antibody response to oligomannose glycans. ACS Chemical Biology 15 (3): 789–798.
52 Redman, R.L. and Krauss, I.J. (2021). Directed evolution of 2′fluoromodified,
RNAsupported carbohydrate clusters that bind tightly to HIV antibody 2G12. Journal of the American Chemical Society 143: 35.
53 Clark, B.E., Auyeung, K., Fregolino, E. etal. (2012). A bacterial
lipooligosaccharide that naturally mimics the epitope of the HIVneutralizing antibody 2G12 as a template for vaccine design. Chemistry & Biology 19 (2): 254–263.
54 Stanfield, R.L., De Castro, C., Marzaioli, A.M. etal. (2015). Crystal structure of the
HIV neutralizing antibody 2G12in complex with a bacterial oligosaccharide analog of mammalian oligomannose. Glycobiology 25 (4): 412–419.
55 Temme, J.S., Drzyzga, M.G., MacPherson, I.S., and Krauss, I.J. (2013). Directed
evolution of 2G12targeted nonamannose glycoclusters by SELMA. Chemistry‐ A European Journal 19 (51): 17291–17295.
56 AgrawalGamse, C., Luallen, R.J., Liu, B. etal. (2011). Yeastelicited crossreactive
antibodies to HIV Env glycans efficiently neutralize virions expressing exclusively highmannose Nlinked glycans. Journal of Virology 85 (1): 470–480.
References
57 Zhang, H., Fu, H., Luallen, R.J. etal. (2015). Antibodies elicited by yeast
glycoproteins recognize HIV1 virions and potently neutralize virions with high mannose Nglycans. Vaccine 33 (39): 5140–5147.
58 Walker, L.M., Phogat, S.K., ChanHui, P.Y. etal. (2009). Broad and potent
neutralizing antibodies from an African donor reveal a new HIV1 vaccine target. Science 326 (5950): 285–289.
59 Bonsignori, M., Hwang, K.K., Chen, X. etal. (2011). Analysis of a clonal lineage
of HIV1 envelope V2/V3 conformational epitopespecific broadly neutralizing antibodies and their inferred unmutated common ancestors. Journal of Virology 85 (19): 9998–10009.
60 Walker, L.M., Huber, M., Doores, K.J. etal. (2011). Broad neutralization coverage
of HIV by multiple highly potent antibodies. Nature 477 (7365): 466–470.
61 DoriaRose, N.A., Schramm, C.A., Gorman, J. etal. (2014). Developmental
pathway for potent V1V2directed HIVneutralizing antibodies. Nature 509 (7498): 55–62.
62 DoriaRose, N.A., Bhiman, J.N., Roark, R.S. etal. (2016). New member of the
V1V2directed CAP256VRC26lineage that shows increased breadth and exceptional potency. Journal of Virology 90 (1): 76–91.
63 Sok, D., van Gils, M.J., Pauthner, M. etal. (2014). Recombinant HIV envelope
trimer selects for quaternarydependent antibodies targeting the trimer apex. Proceedings of the National Academy of Sciences 111 (49): 17624–17629.
64 Doores, K.J. and Burton, D.R. (2010). Variable loop glycan dependency of the
broad and potent HIV1neutralizing antibodies PG9 and PG16. Journal of Virology 84 (20): 10510–10521.
65 McLellan, J.S., Pancera, M., Carrico, C. etal. (2011). Structure of HIV1 gp120 V1/
V2 domain with broadly neutralizing antibody PG9. Nature 480 (7377): 336–343.
66 Amin, M.N., McLellan, J.S., Huang, W. etal. (2013). Synthetic glycopeptides reveal
the glycan specificity of HIVneutralizing antibodies. Nature Chemical Biology 9 (8): 521–526.
67 Toonstra, C., Amin, M.N., and Wang, L.X. (2016). Siteselective chemoenzymatic
glycosylation of an HIV1 polypeptide antigen with two distinct Nglycans via an orthogonal protecting group strategy. The Journal of Organic Chemistry 81 (15): 6176–6185.
68 Pancera, M., ShahzadulHussan, S., DoriaRose, N.A. etal. (2013). Structural
basis for diverse Nglycan recognition by HIV1–neutralizing V1–V2–directed antibody PG16. Nature Structural & Molecular Biology 20 (7): 804–813.
69 Shivatare, S.S., Chang, S.H., Tsai, T.I. etal. (2016). Modular synthesis of
Nglycans and arrays for the heteroligand binding analysis of HIV antibodies. Nature Chemistry 8 (4): 338–346.
70 Shivatare, V.S., Shivatare, S.S., Lee, C.C.D. etal. (2018). Unprecedented role of
hybrid N glycans as ligands for HIV1 broadly neutralizing antibodies. Journal of the American Chemical Society 140 (15): 5202–5210.
71 Aussedat, B., Vohra, Y., Park, P.K. etal. (2013). Chemical synthesis of highly
congested gp120 V1V2 Nglycopeptide antigens for potential HIV1directed vaccines. Journal of the American Chemical Society 135 (35): 13113–13120.
101
3 Carbohydrate-Based Antiviral Vaccines
Данная книга находится в списке для перевода на русский язык сайта https://meduniver.com/
102
72 Alam, S.M., Dennison, S.M., Aussedat, B. etal. (2013). Recognition of synthetic
glycopeptides by HIV1 broadly neutralizing antibodies and their unmutated ancestors. Proceedings of the National Academy of Sciences 110 (45): 18214–18219.
73 Pejchal, R., Doores, K.J., Walker, L.M. etal. (2011). A potent and broad
neutralizing antibody recognizes and penetrates the HIV glycan shield. Science 334 (6059): 1097–1103.
74 Mouquet, H., Scharf, L., Euler, Z. etal. (2012). Complextype Nglycan recognition
by potent broadly neutralizing HIV antibodies. Proceedings of the National Academy of Sciences 109 (47): E3268–E3277.
75 Pantophlet, R., Trattnig, N., Murrell, S. etal. (2017). Bacterially derived synthetic
mimetics of mammalian oligomannose prime antibody responses that neutralize HIV infectivity. Nature Communications 8 (1): 1601.
76 Cai, H., Orwenyo, J., Guenaga, J. etal. (2017). Synthetic multivalent V3
glycopeptides display enhanced recognition by glycandependent HIV1 broadly neutralizing antibodies. Chemical Communications 53 (39): 5453–5456.
77 Orwenyo, J., Cai, H., Giddens, J. etal. (2017). Systematic synthesis and binding
study of HIV V3 glycopeptides reveal the fine epitopes of several broadly neutralizing antibodies. ACS Chemical Biology 12 (6): 1566–1575.
78 Cai, H., Orwenyo, J., Giddens, J.P. etal. (2017). Synthetic threecomponent HIV1
V3 glycopeptide immunogens induce glycandependent antibody responses. Cell Chemical Biology 24 (12): 1513–1522.
79 Cai, H., Zhang, R., Orwenyo, J. etal. (2018). Multivalent antigen presentation
enhances the immunogenicity of a synthetic threecomponent HIV1 V3 glycopeptide vaccine. ACS Central Science 4 (5): 582–589.
80 Cai, H., Zhang, R.S., Orwenyo, J. etal. (2018). Synthetic HIV V3 glycopeptide
immunogen carrying a N334 Nglycan induces glycandependent antibodies with promiscuous site recognition. Journal of Medicinal Chemistry 61 (22): 10116–10125.
81 Alam, S.M., Aussedat, B., Vohra, Y. etal. (2017). Mimicry of an HIV broadly
neutralizing antibody epitope with a synthetic glycopeptide. Science Translational Medicine 9 (381): eaai7521.
82 Francica, J.R., Laga, R., Lynn, G.M. etal. (2019). Star nanoparticles delivering
HIV1 peptide minimal immunogens elicit nearnative envelope antibody responses in nonhuman primates. PLoS Biology 17 (6): e3000328.
83 Haynes, B.F., Kelsoe, G., Harrison, S.C., and Kepler, T.B. (2012). Bcell–lineage
immunogen design in vaccine development with HIV1 as a case study. Nature Biotechnology 30 (5): 423–433.
84 Alexander, D.J. (2000). A review of avian influenza in different bird species.
Veterinary Microbiology 74: 3–13.
85 Zhuang, Q., Wang, S., Liu, S. etal. (2019). Diversity and distribution of type A
influenza viruses: an updated panorama analysis based on protein sequences. Virology Journal 16 (1): 85.
86 Wagner, R., Matrosovich, M., and Klenk, H. (2002). Functional balance between
haemagglutinin and neuraminidase in influenza virus infections. Reviews in Medical Virology 12: 159–166.
References
87 Klenk, H.D., Wagner, R., Heuer, D., and Wolff, T. (2002). Importance of
hemagglutinin glycosylation for the biological functions of influenza virus. Virus Research 82: 73–75.
88 De Jong, N.M.C., Aartse, A., Van Gils, M.J., and Eggink, D. (2020). Development
of broadly reactive influenza vaccines by targeting the conserved regions of the hemagglutinin stem and head domains. Expert Review of Vaccines 19 (6): 563–577.
89 Wilson, I.A., Shekel, J.J., and Wiley, D.C. (1981). Structure of the haemagglutinin
membrane glycoprotein of influenza virus at 3A° resolution. Nature 289: 366–373.
90 Steinhauer, D.A. (1999). Role of hemagglutinin cleavage for the pathogenicity of
influenza virus. Virology 258 (1): 1–20.
91 Worch, R. (2014). Structural biology of the influenza virus fusion peptide. Acta
Biochimica Polonica 61 (3): 421–426.
92 Bouvier, N.M. and Palese, P. (2008). The biology of influenza viruses. Vaccine 26:
D49–D53.
93 Coudeville, L., Bailleux, F., Riche, B. etal. (2010). Relationship between
haemagglutinationinhibiting antibody titres and clinical protection against influenza: development and application of a Bayesian randomeffects model. BMC Medical Research Methodology 10: 18.
94 Bullard, B.L. and Weaver, E.A. (2021). Strategies targeting hemagglutinin as a
universal influenza vaccine. Vaccine 9 (3): 257.
95 Eggink, D., Goff, P.H., and Palese, P. (2014). Guiding the immune response against
influenza virus hemagglutinin toward the conserved stalk domain by hyperglycosylation of the globular head domain. Journal of Virology 88 (1): 699–704.
96 Lin, S.C., Liu, W.C., Jan, J.T., and Wu, S.C. (2014). Glycan masking of
hemagglutinin for adenovirus vector and recombinant protein immunizations elicits broadly neutralizing antibodies against H5N1 avian influenza viruses. PLoS One 9 (3): e92822.
97 Lin, S.C., Lin, Y.F., Chong, P., and Wu, S.C. (2012). Broader neutralizing
antibodies against H5N1 viruses using primeboost immunization of hyperglycosylated hemagglutinin DNA and viruslike particles. PLoS One 7 (6): 1–8.
98 Nguyen, Q.T. and Choi, Y.K. (2021). Targeting antigens for universal influenza
vaccine development. Viruses 13 (6): 973.
99 Ulmer, J.B., DeWitt, C.M., Chastain, M. etal. (1999). Enhancement of DNA
vaccine potency using conventional aluminum adjuvants. Vaccine 18: 18–28.
100 Tregoning, J.S., Russell, R.F., and Kinnear, E. (2018). Adjuvanted influenza
vaccines. Human Vaccines & Immunotherapeutics 14: 550–564.
101 Hung, J.T., Tsai, Y.C., Der Lin, W. etal. (2014). Potent adjuvant effects of novel
NKT stimulatory glycolipids on hemagglutinin based DNA vaccine for H5N1influenza virus. Antiviral Research 107 (1): 110–118.
102 Natori, T., Koezuka, Y., and Higa, T. (1993). Agelasphins, novel
αgalactosylceramides from the marine sponge Agelas mauritianus. Tetrahedron Letters 34 (35): 5591–5592.
103
3 Carbohydrate-Based Antiviral Vaccines
Данная книга находится в списке для перевода на русский язык сайта https://meduniver.com/
104
103 Morita, M., Motoki, K., Akimoto, K. etal. (1995). Structureactivity relationship of
αgalactosylceramides against B16bearing mice. Journal of Medicinal Chemistry 38 (12): 2176–2187.
104 Guillonneau, C., Mintern, J.D., Hubert, F.X. etal. (2009). Combined NKT cell
activation and influenza virus vaccination boosts memory CTL generation and protective immunity. Proceedings of the National Academy of Sciences of the United States of America 106: 3330–3335.
105 Artiaga, B.L., Yang, G., Hackmann, T.J. etal. (2016). αgalactosylceramide protects
swine against influenza infection when administered as a vaccine adjuvant. Scientific Reports 6: 23593.
106 Dölen, Y., Kreutz, M., Gileadi, U. etal. (2016). Codelivery of PLGA encapsulated
invariant NKT cell agonist with antigenic protein induce strong T cellmediated antitumor immune responses. Oncoimmunology 5 (1): e1068493.
107 Lang, S. and Huang, X. (2020). Carbohydrate conjugates in vaccine developments.
Frontiers in Chemistry 8 (April): 1–25.
108 Anderson, R.J., Li, J., Kedzierski, L. etal. (2017). Augmenting influenzaspecific
T cell memory generation with a natural killer T celldependent glycolipidpeptide vaccine. ACS Chemical Biology 12 (11): 2898–2905.
109 Wilkinson, T.M., Li, C.K., Chui, C.S. etal. (2012). Preexisting influenzaspecific
+
T cells correlate with disease protection against influenza challenge in
CD4 humans. Nature Medicine 18: 274–280.
110 AbdelMotal, U.M., Guay, H.M., Wigglesworth, K. etal. (2007). Immunogenicity
of influenza virus vaccine is increased by antigalmediated targeting to antigen presenting cells. Journal of Virology 81 (17): 9131–9141.
111 Henion, T.R., Gerhard, W., Anaraki, F., and Galili, U. (1997). Synthesis of αgal
epitopes on influenza virus vaccines, by recombinant α1,3galactosyltransferase, enables the formation of immune complexes with the natural antiGal antibody. Vaccine 15 (11): 1174–1182.
112 von Itzstein, M. (2007). The war against influenza: discovery and development of
sialidase inhibitors. Nature Reviews. Drug Discovery 6: 967–974.
113 Wohlbold, T.J. and Krammer, F. (2014). In the shadow of hemagglutinin: a
growing interest in influenza viral neuraminidase and its role as a vaccine antigen. Viruses 6 (6): 2465–2494.
114 Chen, Y.Q., Wohlbold, T.J., Zheng, N.Y. etal. (2018). Influenza infection in
humans induces broadly crossreactive and protective neuraminidasereactive antibodies. Cell 173 (2): 417–429.e10.
115 Gilchuk, I.M., Bangaru, S., Gilchuk, P. etal. (2019). Influenza H7N9 virus
neuraminidasespecific human monoclonal antibodies inhibit viral egress and protect from lethal influenza infection in mice. Cell Host & Microbe 26 (6): 715–728.
116 Trombetta, C.M. and Montomoli, E. (2016). Influenza immunology evaluation and
correlates of protection: a focus on vaccines. Expert Review of Vaccines 15 (8): 967–976.
117 Krammer, F., Fouchier, R.A.M., Eichelberger, M.C. etal. (2018). NAction! how can
neuraminidasebased immunity contribute to better influenza virus vaccines? mBio 9 (2): e02332–e02317.
References
118 Wan, H., Yang, H., Shore, D.A. etal. (2015). Structural characterization of a
protective epitope spanning A(H1N1)pdm09influenza virus neuraminidase monomers. Nature Communications 6: 6114.
119 Zhu, X., Turner, H.L., Lang, S. etal. (2019). Structural basis of protection against
H7N9influenza virus by human antiN9neuraminidase antibodies. Cell Host & Microbe 26 (6): 729–738.e4.
120 Bachelder, E.M., Beaudette, T.T., Broaders, K.E. etal. (2008). Acetalderivatized
dextran: an acidresponsive biodegradable material for therapeutic applications. Journal of the American Chemical Society 130 (32): 10494–10495.
121 Bachelder, E.M., Beaudette, T.T., Broaders, K.E. etal. (2010). In vitro analysis of
acetalated dextran microparticles as a potent delivery platform for vaccine adjuvants. Molecular Pharmaceutics 7 (3): 826–835.
122 Junkins, R.D., Gallovic, M.D., Johnson, B.M. etal. (2018). A robust microparticle
platform for a STINGtargeted adjuvant that enhances both humoral and cellular immunity during vaccination. Journal of Controlled Release 270: 1–13.
123 Chen, N., Johnson, M.M., Collier, M.A. etal. (2018). Tunable degradation of
acetalated dextran microparticles enables controlled vaccine adjuvant and antigen delivery to modulate adaptive immune responses. Journal of Controlled Release 273: 147–159.
124 Matrosovich, M. and Klenk, H.D. (2003). Natural and synthetic sialic acid
containing inhibitors of influenza virus receptor binding. Reviews in Medical Virology 13 (2): 85–97.
125 Bhatia, S., Dimde, M., and Haag, R. (2014). Multivalent glycoconjugates as
vaccines and potential drug candidates. MedChemComm 5 (7): 862–878.
126 Lees, W.J., Spaltenstein, A., Kingerywood, J.E., and Whitesides, G.M. (1994).
Polyacrylamides bearing pendant asialoside groups strongly inhibit agglutination of erythrocytes by influenza A virus: multivalency and steric stabilization of particulate biological system. Journal of Medicinal Chemistry 37 (20): 3419–3433.
127 Sigal, G.B., Mammen, M., Dahmann, G., and Whitesides, G.M. (1996).
Polyacrylamides bearing pendant αsialoside groups strongly inhibit agglutination of erythrocytes by influenza virus: the strong inhibition reflects enhanced binding through cooperative polyvalent interactions. Journal of the American Chemical Society 118: 3789–3800.
128 Mammen, M., Dahmann, G., and Whitesides, G.M. (1995). Effective inhibitors of
hemagglutination by influenza virus synthesized from polymers having active ester groups. Insight into mechanism of inhibition. Journal of Medicinal Chemistry 38 (21): 4179–4190.
129 Gambaryan, A.S., Tuzikov, A.B., Chinarev, A.A. etal. (2002). Polymeric inhibitor
of influenza virus attachment protects mice from experimental influenza infection. Antiviral Research 55 (1): 201–205.
130 Kwon, S.J., Na, D.H., Kwak, J.H. etal. (2017). Nanostructured glycan architecture
is important in the inhibition of influenza A virus infection. Nature Nanotechnology 12 (1): 48–54.
131 Papp, I., Sieben, C., Ludwig, K. etal. (2010). Inhibition of influenza virus infection by
multivalent sialicacid functionalized gold nanoparticles. Small 6 (24): 2900–2906.
105
Соседние файлы в папке Библиотека им академика М.И. Перельмана
Помощь Обратная связь Вопросы и предложения Пользовательское соглашение Политика конфиденциальности